D. Lee, M. Yu, E. Lee, H. Kim, Y. Yang et al., Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium, J Clin Invest, vol.119, pp.2702-2715, 2009.

Y. Lazrek, O. Dubreuil, V. Garambois, N. Gaborit, C. Larbouret et al., Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation, Neoplasia N Y N, vol.15, pp.335-382, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00815985

S. Wang, X. Huang, C. Lee, and B. Liu, Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin, Oncogene, vol.29, pp.4225-4261, 2010.

S. Wang, J. Huang, H. Lyu, B. Cai, X. Yang et al., Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer, Breast Cancer Res BCR, vol.15, p.101, 2013.

L. E. French and J. Tschopp, Protein-based therapeutic approaches targeting death receptors, Cell Death Differ, vol.10, pp.117-140, 2003.

Z. Mahmood and Y. Shukla, Death receptors: targets for cancer therapy, Exp Cell Res, vol.316, pp.887-99, 2010.

H. Wajant, Death receptors, Essays Biochem, vol.39, pp.53-71, 2003.

L. S. Dickens, R. S. Boyd, J. , R. Hughes, M. A. Robinson et al., A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death, Mol Cell, vol.47, pp.291-305, 2012.

K. Schleich, U. Warnken, N. Fricker, S. Oztürk, P. Richter et al., Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model, Mol Cell, vol.47, pp.306-325, 2012.

J. Lemke, S. Von-karstedt, J. Zinngrebe, and H. Walczak, Getting TRAIL back on track for cancer therapy, Cell Death Differ, vol.21, pp.1350-64, 2014.

Z. T. Schug, F. Gonzalvez, R. H. Houtkooper, F. M. Vaz, and E. Gottlieb, BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane, Cell Death Differ, vol.18, pp.538-586, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00592286

D. Westphal, R. M. Kluck, and G. Dewson, Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis, Cell Death Differ, vol.21, pp.196-205, 2014.

H. Walczak, Death receptor-ligand systems in cancer, cell death, and inflammation, Cold Spring Harb Perspect Biol, vol.5, p.8698, 2013.

L. Humphreys, M. Espona-fiedler, and D. B. Longley, FLIP as a therapeutic target in cancer, FEBS J, vol.285, pp.4104-4127, 2018.

S. Horn, M. A. Hughes, R. Schilling, C. Sticht, T. Tenev et al., Caspase-10 negatively regulates Caspase-8-mediated cell death, switching the response to CD95L in favor of NF-?B activation and cell survival, Cell Rep, vol.19, pp.785-97, 2017.

M. A. Hughes, I. R. Powley, J. , R. Horn, S. Feoktistova et al., Co-operative and hierarchical binding of c-FLIP and Caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate, Mol Cell, vol.61, pp.834-883, 2016.

K. Schleich, J. H. Buchbinder, S. Pietkiewicz, T. Kähne, U. Warnken et al., Molecular architecture of the DED chains at the DISC: regulation of procaspase-8 activation by short DED proteins c-FLIP and procaspase-8 prodomain, Cell Death Differ, vol.23, pp.681-94, 2016.

C. Haag, D. Stadel, S. Zhou, M. G. Bachem, P. Möller et al., Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells, Gut, vol.60, pp.225-262, 2011.

T. W. Day, S. Huang, and A. R. Safa, C-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells, Biochem Pharmacol, vol.76, pp.1694-704, 2008.

X. Zhang, L. Zhang, H. Yang, X. Huang, H. Otu et al., c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells, Cancer Res, vol.67, pp.9425-9459, 2007.

T. R. Wilson, K. M. Mclaughlin, M. Mcewan, H. Sakai, K. Rogers et al., C-FLIP: a key regulator of colorectal cancer cell death, Cancer Res, vol.67, pp.5754-62, 2007.

A. Panner, C. D. James, M. S. Berger, and R. O. Pieper, mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells, Mol Cell Biol, vol.25, pp.8809-8832, 2005.

G. Valente, F. Manfroi, C. Peracchio, G. Nicotra, R. Castino et al., cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy, Br J Haematol, vol.132, pp.560-70, 2006.

M. Valnet-rabier, B. Challier, S. Thiebault, R. Angonin, G. Margueritte et al., c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome, Br J Haematol, vol.128, pp.767-73, 2005.

A. R. Safa and K. E. Pollok, Targeting the anti-apoptotic protein c-FLIP for Cancer therapy, Cancers, vol.3, pp.1639-71, 2011.

L. Chang, H. Kamata, G. Solinas, J. Luo, S. Maeda et al., The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover, Cell, vol.124, pp.601-614, 2006.

A. Panner, C. A. Crane, C. Weng, A. Feletti, S. Fang et al., Ubiquitinspecific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme, Cancer Res, vol.70, pp.5046-53, 2010.

L. Piggott, A. Silva, T. Robinson, A. Santiago-gómez, B. M. Simões et al., Acquired resistance of ER-positive breast Cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through posttranslational downregulation of c-FLIP, Clin Cancer Res Off J Am Assoc Cancer Res, vol.24, pp.2452-63, 2018.

M. R. Abedini, E. J. Muller, R. Bergeron, D. A. Gray, and B. K. Tsang, Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatininduced, p53-dependent ubiquitination of FLICE-like inhibitory protein, Oncogene, vol.29, pp.11-25, 2010.

M. R. Abedini, E. J. Muller, J. Brun, R. Bergeron, D. A. Gray et al., Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells, Cancer Res, vol.68, pp.4511-4518, 2008.

F. Yang, K. H. Tay, L. Dong, R. F. Thorne, C. C. Jiang et al., Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells, Cell Death Differ, vol.17, pp.1354-67, 2010.

L. Clorennec, C. Bazin, H. Dubreuil, O. Larbouret, C. Ogier et al., Neuregulin 1 allosterically enhances the antitumor effects of the noncompeting anti-HER3 antibody 9F7-F11 by increasing its binding to HER3, Mol Cancer Ther, vol.16, pp.1312-1335, 2017.

L. Clorennec, C. Lazrek, Y. Dubreuil, O. Larbouret, C. Poul et al., The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2-dependent ITCH/AIP4 activation, Oncotarget, vol.7, issue.24, pp.37013-37042, 2016.

M. Malm, F. Y. Frejd, S. Ståhl, and J. Löfblom, Targeting HER3 using mono-and bispecific antibodies or alternative scaffolds, mAbs, vol.8, pp.1195-209, 2016.

W. Jacob, I. James, M. Hasmann, and M. Weisser, Clinical development of HER3-targeting monoclonal antibodies: perils and progress, Cancer Treat Rev, vol.68, pp.111-134, 2018.

G. Thomas, T. Chardès, N. Gaborit, C. Mollevi, W. Leconet et al., HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models, Oncotarget, vol.5, pp.7138-7186, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01075330

R. Mouchantaf, B. A. Azakir, P. S. Mcpherson, S. M. Millard, S. A. Wood et al., The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X, J Biol Chem, vol.281, pp.38738-38785, 2006.

E. Gallagher, M. Gao, Y. Liu, and K. M. , Activation of the E3 ubiquitin ligase itch through a phosphorylation-induced conformational change, Proc Natl Acad Sci, vol.103, pp.1717-1739, 2006.

M. Jeong, E. Lee, D. Seong, J. Seo, J. Kim et al., USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability, Oncogene, vol.36, pp.458-70, 2017.

M. Rossi, B. Rotblat, A. K. Amelio, I. Caraglia, M. Misso et al., High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy, Cell Death Dis, vol.5, p.1203, 2014.

M. Rossi, E. R. Munarriz, S. Bartesaghi, M. Milanese, D. Dinsdale et al., Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux, J Cell Sci, vol.122, pp.3330-3339, 2009.

B. Gillissen, F. Essmann, V. Graupner, L. Stärck, S. Radetzki et al., Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway, EMBO J, vol.22, pp.3580-90, 2003.

J. Silke and J. Vince, IAPs and cell death, Curr Top Microbiol Immunol, vol.403, pp.95-117, 2017.

K. Engel, M. Rudelius, J. Slawska, L. Jacobs, A. Abhari et al., USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma, EMBO Mol Med, vol.8, pp.851-62, 2016.

L. Fattore, D. Malpicci, E. Marra, F. Belleudi, A. Noto et al., Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma, Oncotarget, vol.6, pp.24823-24864, 2015.

A. Noto, D. Vitis, C. Roscilli, G. Fattore, L. Malpicci et al., Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer, Oncotarget, vol.4, pp.1253-65, 2013.

H. Lee, H. Lee, H. Chin, K. Kim, and D. Lee, ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells, Oncotarget, vol.5, pp.5138-52, 2014.

F. Belleudi, E. Marra, F. Mazzetta, L. Fattore, M. R. Giovagnoli et al., Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells, Cell Cycle Georget Tex, vol.11, pp.1455-67, 2012.
URL : https://hal.archives-ouvertes.fr/pasteur-00961644

N. Gaborit, A. Abdul-hai, M. Mancini, M. Lindzen, S. Lavi et al., Examination of HER3 targeting in cancer using monoclonal antibodies, Proc Natl Acad Sci U S A, vol.112, pp.839-883, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02276327

S. Byun, S. Lee, J. Lee, C. Jeong, F. L. Lim et al., USP8 is a novel target for overcoming gefitinib resistance in lung cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.19, pp.3894-904, 2013.

M. Shun, Y. W. Park, S. Sanders, B. G. Kline, and K. , Downregulation of epidermal growth factor receptor expression contributes to alpha-TEA's Proapoptotic effects in human ovarian Cancer cell lines, J Oncol, p.824571, 2010.

S. Prasad, V. R. Yadav, J. Ravindran, and B. B. Aggarwal, ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins, Cancer Res, vol.71, pp.538-587, 2011.

S. Yodkeeree, B. Sung, P. Limtrakul, and B. B. Aggarwal, Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species, Cancer Res, vol.69, pp.6581-6590, 2009.

C. Chen, Y. Liu, and D. Zheng, An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells, Cell Res, vol.19, pp.984-95, 2009.

R. Stein, P. Gupta, X. Chen, T. M. Cardillo, R. R. Furman et al., Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways, Blood, vol.115, pp.5180-90, 2010.

K. A. Sarosiek, X. Chi, J. A. Bachman, J. J. Sims, J. Montero et al., BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response, Mol Cell, vol.51, pp.751-65, 2013.

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations